FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553996929> ?p ?o ?g. }

• W2553996929 abstract "Background Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). The therapeutic strategy to adopt in aPL patients during pregnancy should in fact consider different clinical and serological risk factors. In addition to conventional therapy, some recent evidences suggest a possible role of hydroxychloroquine. Objectives To review our approach in first-line treated pregnancies in aPL patients in our 30 years9 experience Pregnancy Clinic (1985 -2015) to find out which clinical and serological risk factors have influenced the choice of treatments and which should be considered in the future for possible additional treatments. Methods We reviewed 120 first-treated pregnancies that were prospectively followed in our center by a multispecialistic team of Rheumatologists and Obstetricians. Patients were classified as Primary Antiphospholipid Syndrome (PAPS) according to revised criteria and as Incomplete PAPS or aPL carriers according to their clinical history or aPL status. Patients with concomitant systemic autoimmune diseases were excluded. aPL profile was defined as the combination of the 3 criteria tests for aPL (Lupus Anticoagulant, anti-cardiolipin, anti-Beta2 Glycoprotein I). APO was defined as at least one of the followings: miscarriage ( Results The type of therapy was divided in three main categories: combination therapy with low molecular weight heparin (LMWH) and LDA (68,57%), single therapy with low dose aspirin (LDA) (31,26%) and therapy with corticosteroids plus LDA (21,18%). We collected 16 APO (13%): 11 (75%) in the category of LMWH+LDA. Analyzing APO vs. non-APO pregnancies we found no differences in variables that could predict an APO (history of thrombosis, a previous APO or a triple positive aPL profile) in any of the 3 categories (Table 1). Moreover, we found an increased rate of non criteria aPL manifestations in APO patients in LMWH+ASA category (31% vs. 4%, p:0.002; OR 2.19, 95%CI 2.20–61.6), but not in the other 2 categories of treatment. Conclusions Non-criteria aPL manifestations are a risk factor for APO ande can determine failure to conventional treatment with LMWH plus LDA during pregnancy in aPL patients regardless of clinical diagnosis, serological profile or obstetric history. These patients may represent a more severe phenotype of disease and may deserve an immunomodulatory treatment to increase the probability of success during pregnancy. Disclosure of Interest None declared" @default.
• W2553996929 created "2016-11-30" @default.
• W2553996929 creator A5013868891 @default.
• W2553996929 creator A5015839474 @default.
• W2553996929 creator A5026763784 @default.
• W2553996929 creator A5038039615 @default.
• W2553996929 creator A5059066891 @default.
• W2553996929 creator A5061119590 @default.
• W2553996929 creator A5062337379 @default.
• W2553996929 creator A5079447134 @default.
• W2553996929 creator A5079883376 @default.
• W2553996929 creator A5080062326 @default.
• W2553996929 date "2016-06-01" @default.
• W2553996929 modified "2023-09-27" @default.
• W2553996929 title "THU0300 Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholipid Antibodies-Positive Women According To Different Treatment Strategies: Results from Our 30 Years'Experience Pregnancy Clinic" @default.
• W2553996929 doi "https://doi.org/10.1136/annrheumdis-2016-eular.4593" @default.
• W2553996929 hasPublicationYear "2016" @default.
• W2553996929 type Work @default.
• W2553996929 sameAs 2553996929 @default.
• W2553996929 citedByCount "0" @default.
• W2553996929 crossrefType "journal-article" @default.
• W2553996929 hasAuthorship W2553996929A5013868891 @default.
• W2553996929 hasAuthorship W2553996929A5015839474 @default.
• W2553996929 hasAuthorship W2553996929A5026763784 @default.
• W2553996929 hasAuthorship W2553996929A5038039615 @default.
• W2553996929 hasAuthorship W2553996929A5059066891 @default.
• W2553996929 hasAuthorship W2553996929A5061119590 @default.
• W2553996929 hasAuthorship W2553996929A5062337379 @default.
• W2553996929 hasAuthorship W2553996929A5079447134 @default.
• W2553996929 hasAuthorship W2553996929A5079883376 @default.
• W2553996929 hasAuthorship W2553996929A5080062326 @default.
• W2553996929 hasConcept C126322002 @default.
• W2553996929 hasConcept C131872663 @default.
• W2553996929 hasConcept C159654299 @default.
• W2553996929 hasConcept C203014093 @default.
• W2553996929 hasConcept C2776874634 @default.
• W2553996929 hasConcept C2776884760 @default.
• W2553996929 hasConcept C2779123688 @default.
• W2553996929 hasConcept C2779134260 @default.
• W2553996929 hasConcept C2779234561 @default.
• W2553996929 hasConcept C2779245376 @default.
• W2553996929 hasConcept C2780022809 @default.
• W2553996929 hasConcept C2780625311 @default.
• W2553996929 hasConcept C2780868729 @default.
• W2553996929 hasConcept C3008058167 @default.
• W2553996929 hasConcept C45189115 @default.
• W2553996929 hasConcept C524204448 @default.
• W2553996929 hasConcept C54355233 @default.
• W2553996929 hasConcept C71924100 @default.
• W2553996929 hasConcept C86803240 @default.
• W2553996929 hasConceptScore W2553996929C126322002 @default.
• W2553996929 hasConceptScore W2553996929C131872663 @default.
• W2553996929 hasConceptScore W2553996929C159654299 @default.
• W2553996929 hasConceptScore W2553996929C203014093 @default.
• W2553996929 hasConceptScore W2553996929C2776874634 @default.
• W2553996929 hasConceptScore W2553996929C2776884760 @default.
• W2553996929 hasConceptScore W2553996929C2779123688 @default.
• W2553996929 hasConceptScore W2553996929C2779134260 @default.
• W2553996929 hasConceptScore W2553996929C2779234561 @default.
• W2553996929 hasConceptScore W2553996929C2779245376 @default.
• W2553996929 hasConceptScore W2553996929C2780022809 @default.
• W2553996929 hasConceptScore W2553996929C2780625311 @default.
• W2553996929 hasConceptScore W2553996929C2780868729 @default.
• W2553996929 hasConceptScore W2553996929C3008058167 @default.
• W2553996929 hasConceptScore W2553996929C45189115 @default.
• W2553996929 hasConceptScore W2553996929C524204448 @default.
• W2553996929 hasConceptScore W2553996929C54355233 @default.
• W2553996929 hasConceptScore W2553996929C71924100 @default.
• W2553996929 hasConceptScore W2553996929C86803240 @default.
• W2553996929 hasLocation W25539969291 @default.
• W2553996929 hasOpenAccess W2553996929 @default.
• W2553996929 hasPrimaryLocation W25539969291 @default.
• W2553996929 isParatext "false" @default.
• W2553996929 isRetracted "false" @default.
• W2553996929 magId "2553996929" @default.
• W2553996929 workType "article" @default.